Article
Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER- breast cancer.
JCI insight - 22 Aug 2025
Ridnour Lisa A, Cheng Robert Ys, Heinz William F, Pore Milind, Gonzalez Ana L, Femino Elise L, Moffat Rebecca L, Wink Adelaide L, Imtiaz Fatima, Coutinho Leandro L, Butcher Donna, Edmondson Elijah F, Rangel M Cristina, Wong Stephen Tc, Lipkowitz Stanley, Glynn Sharon A, Vitek Michael P, McVicar Daniel W, Li Xiaoxian, Anderson Stephen K, Paolocci Nazareno, Hewitt Stephen M, Ambs Stefan, Billiar Timothy R, Chang Jenny C, Lockett Stephen J, Wink David A
Abstract excerpt
Tumor immunosuppression affects survival and treatment efficacy. Tumor NOS2/COX2 coexpression strongly predicts poor outcome in estrogen receptor-negative (ER-) breast cancer by promoting metastasis, drug resistance, cancer stemness, and immune suppression. Herein, a spatially distinct NOS2/COX2 and CD3+CD8+PD1- T effector (TEff) cell landscape correlated with poor survival in ER- tumors. NOS2 was primarily...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
